

Development of a Novel Triple Agonist(HM15275)-Based Transdermal Drug Delivery System for Obesity Treatment

Hanmi Pharm. Co., Ltd.

Global · R&D 선도



METABOLIC	Preclinical
Product Type	rProtein
Indication	Obesity
Target	GLP-1, GIP and Glucagon receptor (Triple agonist)
MoA(Mechanism of Action)	HM15275 is a GLP-1 / GIP / Glucagon triple receptor agonist taken once a week: - GLP-1: Reduces appetite and controls blood sugar. - GIP: Maximizes weight loss and reduces stomach side effects (like nausea). - Glucagon: Burns fat and increases energy expenditure by "browning" fat cells.
Competitiveness	HM15275 is best-in class drug among the same family of drugs. - Higher Weight Loss Efficiency: Aims for over 25% weight loss, targeting results close to weight-loss surgery (surpassing current 15-20% drugs). - Muscle Preservation: Maximizes fat loss while saving muscle, preventing the common "yo-yo effect" (weight rebound). - The Best "Switching" Option: Proven to break the weight-loss plateau for patients who no longer lose weight on existing drugs like tirzepatide. - Beyond Obesity: Provides multi-benefits for Diabetes, Fatty Liver (MASH), and Heart/Kidney health.
Development Stage	Preclinical
Route of Administration	Transdermal (Microneedle system)

Any unauthorized distribution or reproduction of this material is strictly prohibited.